Skip to content.

Aptose Biosciences Inc. announces it entered into a $25M Committed Equity Facility

Date Announced

May 25, 2023

Lead Office

Québec City


25.00 Million USD

On May 25, 2023, Aptose Biosciences Inc. ("Aptose"), entered into a common share purchase agreement and registration rights agreement with an institutional investor. The agreement governs a Committed Equity Facility, which grants Aptose the right to sell and issue up to $25 million of its shares over 24 months to the investor. The securities offered are not registered under the 1933 Securities Act and will not be offered or sold in the United States. Common Shares will not be sold on the Toronto Stock Exchange or other Canadian Trading Markets.

Aptose, headquartered in Toronto, Ontario, is a biopharmaceutical company. It focuses on the discovery, research and development of anti-cancer therapies.

McCarthy Tétrault advised Aptose with a team led by Charles-Antoine Souliere that included Asma Boudoukha (Business).